Not logged in Share Save
Share Save
Share Save
Share Save
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis (vol 23, pg 1130, 2012) Cortes, J.; Calvo, V.; Ramirez-Merino, N.; O'Shaughnessy, J.; Brufsky, A.; Robert, N.; Vidal, M.; Munoz, E.; Perez, J.; Dawood, S.; Saura, C.; Di Cosimo, S.; Gonzalez-Martin, A.; Bellet, M.; Silva, O. E.; Miles, D.; Llombart, A.; Baselga, J. Share Save
Share Save
Share Save
Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results Brufsky, A.; Kim, S-B; Velu, T.; Garcia-Saenz, J. A.; Tan-Chiu, E.; Sohn, J. H.; Dirix, L.; Borms, M. V.; Liu, M-C; Moezi, M. M.; Kozloff, M. F.; Sparano, J. A.; Xu, N.; Wongchenko, M.; Simmons, B.; McNally, V.; Miles, D. Share Save
Share Save
Share Save
Share Save
Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study Dieras, V.; Miles, D.; Verma, S.; Pegram, M.; Welslau, M.; Baselga, J.; Krop, I.; Blackwell, K.; Kang, B.; Xu, J.; Green, M.; Gianni, L. Share Save
Biomarker (BM) results from MERiDiAN, a double-blind placebo (PLA)-controlled randomized phase 3 trial of 1st-line paclitaxel (PAC) with or without bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC) Das Thakur, M.; Bais, C.; Estay, I.; Vaidyanathan, R.; O'Shaughnessy, J.; Cameron, D.; Hubeaux, S.; Quah, C.; Miles, D. Share Save
Share Save
Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) Miles, D.; Puglisi, F.; Schneeweiss, A.; Ciruelos, E.; Peretz-Yablonski, T.; Moreno, K.; Restuccia, E.; Lasserre, S.; Bachelot, T. Share Save
First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) plus /- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC) Miles, D.; Cameron, D.; Bondarenko, I.; Lyudmila, M.; Alcedo, J. C.; Lopez, R. I.; Im, S. A.; Canon, J. L.; Shparyk, Y.; Yardley, D.; Masuda, N.; Ro, J.; Hubeaux, S.; Quah, C.; Bais, C.; O'Shaughnessy, J. Share Save
Share Save
Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer Woolf, D. K.; Beresford, M.; Li, S. P.; Dowsett, M.; Sanghera, B.; Wong, W. L.; Sonoda, L.; Detre, S.; Amin, V.; Ah-See, M-L; Miles, D.; Makris, A. Share Save
Share Save
Evaluation of FLT PET-CT as an imaging biomarker of proliferation in primary breast cancer Woolf, D. K.; Beresford, M.; Li, S. P.; Sanghera, B.; Wong, W. L.; Amin, V.; Ah-See, M-L; Miles, D.; Sonoda, L.; Detre, S.; Dowsett, M.; Makris, A. Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
.png)
CANCER RESEARCH.png)
